CareFusion Announces Completion Of Post-Market Surveillance For MaxPlus® Positive Displacement Needleless Connectors
Data from CMS Hospital Compare database showing hospitals using MaxPlus® had lower infection rates compared to hospitals not using MaxPlus
Sep 4, 2014
SAN DIEGO, CA, Sept. 4, 2014 – CareFusion (NYSE:CFN), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has notified the company that it has fully completed its obligations for Post-market Surveillance Studies for the MaxPlus® line of positive displacement needleless connectors.
In an Aug. 6 letter to CareFusion, FDA officials cited multiple studies conducted by CareFusion that showed MaxPlus positive displacement needleless connectors had no evidence of higher infection rates as compared to other neutral or negative displacement needleless connectors. The letter highlighted an analysis of the CMS’ Hospital Compare database suggesting that in 2013, hospitals using MaxPlus positive displacement needleless connectors had lower unadjusted central line associated blood stream infection (CLABSI) rates, as well as lower standardized infection ratios, compared to hospitals not using MaxPlus. These assessments were based on data from 3,074 hospitals, accounting for nearly 11,000 CLABSIs associated with approximately 10 million catheter days.
“We have always believed in the design of the MaxPlus needleless connector,” said Jim Paloyan, vice president of Americas Infusion Specialty Disposables for CareFusion. “The data from nearly 10 million catheter days suggesting lower infection rates for hospitals using MaxPlus are a powerful testament to the design and function of our product.”
All manufacturers of positive displacement connectors were required by the FDA to perform post-market surveillance. Manufacturers were asked to provide data to show that the rate of bloodstream infections for patients receiving a positive displacement needleless connector for central line access is statistically non-inferior to the rates seen in subjects receiving other needleless connectors for central line access, given comparable patient populations. Through the completion of this study, CareFusion has no further post-market surveillance requirements from the FDA concerning the MaxPlus needleless connector.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
For more information on BD, please visit bd.com.
Back to News Releases